Wells Fargo analyst Larry Biegelsen raised the firm’s price target on Boston Scientific (BSX) to $124 from $118 and keeps an Overweight rating on the shares. The firm says Boston Scientific reported Q2 revenue/EPS ahead of Street on strong PFA and Watchman strength. It raised 2025 organic growth guidance to 14%-15% and EPS guidance to $2.95-$2.99.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific price target raised to $133 from $125 at Barclays
- Boston Scientific Reports Strong Q2 2025 Results
- Boston Scientific Reports Strong Q2 Growth Amid Challenges
- Boston Scientific’s Strong Financial Performance and Positive Outlook Earns Buy Rating
- Boston Scientific’s Strong Performance and Growth Potential Reinforce Buy Rating